Eighteen-month androgen-deprivation therapy plus radiotherapy recommended standard for patients with high-risk prostate cancer

Reducing the duration of androgen-deprivation therapy with radiotherapy from 36 months to 18 months is safe and may represent a new standard of care for patients with high-risk prostate cancer, according to data presented at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.
Prostate Cancer Advisor